tirasemtiv

Themes discussed at a recent symposium included immune system modulation, combatting toxic proteins and genetic material, replacing or repairing damaged cells, and improving muscle function

Posted on Friday, December 20, 2013 - 10:25, By: Margaret Wahl
"We are undoubtedly slowing down the MND [motor neuron disease] supertanker, and can start to see how we might turn it around for the first tim," said Martin Turner, senior clinician scientist at the University of Oxford (United Kingdom), on research being reported on at the 24th International...

Six short items about the state of ALS science: Neuralstem and Cytokinetics ALS clinical trials; weight maintenance in ALS; stem cell technology; and more

Posted on Thursday, September 12, 2013 - 05:00, By: Amy Madsen
This roundup of recent amyotrophic lateral sclerosis (ALS) research and clinical trials news includes:

58 trial participants mistakenly received a placebo instead of the test drug for part of the BENEFIT-ALS clinical trial of tirasemtiv in ALS

Posted on Monday, July 8, 2013 - 04:35, By: Amy Madsen
Update (Dec. 12, 2013): Cytokinetics announced in a Dec. 8, 2013, press release, that the BENEFIT-ALS trial is now fully enrolled and includes 711 participants. Lead investigator Jeremy Shefner presented a discussion of this study at the 24th International Symposium on ALS/MND, held in Milan,...

An interactive graphic provides details about six drugs currently being tested in the fight against ALS

Posted on Wednesday, May 1, 2013 - 09:30, By: Amy Madsen
Research seeking therapies for ALS is advancing at a rapid pace, and there are more potential treatments in clinical trials than ever before. Here, we look at six drugs currently in clinical trials for ALS: arimoclomol, Gilenya, ozanezumab, pyrimethamine, rasagiline and tirasemtiv. How to use the...
Posted on Wednesday, May 1, 2013 - 09:23, By: Amy Madsen
Name: Tirasemtiv (CK-2017357) How it works: Tirasemtiv, developed by Cytokinetics, is designed to increase the sensitivity of muscle fibers to calcium, resulting in a potential increase in muscle force generation.

Updates on several important clinical trials were presented at an international ALS conference in December, including reports on ISIS-SOD1-Rx, NP001, neural stem cells, olesoxime and tirasemtiv

Posted on Thursday, December 13, 2012 - 16:11, By: Amy Madsen
The 23rd International Symposium on ALS/MND (motor neuron disease), held in Chicago Dec. 5-7, 2012, brought together more than 900 researchers, clinicians and other health care professionals from 30 countries to hear presentations on the latest in ALS care and research.

South San Francisco biotech Cytokinetics has opened a 400-person clinical trial to evaluate the safety, tolerability and efficacy of tirasemtiv (formerly CK-2017357) in people with ALS

Posted on Thursday, September 20, 2012 - 05:00, By: Amy Madsen
Update (Dec. 30, 2013): According to a Dec. 3, 2013, press release from Cytokinetics, this trial is closed to new participants. More than 700 patients have enrolled, and results are expected in the first half of 2014.

Advertisements

myMuscleTeam